Premium
ACE2: Its potential role and regulation in severe acute respiratory syndrome and COVID‐19
Author(s) -
Rezaei Mitrasadat,
Ziai Seyed Ali,
Fakhri Sajad,
Pouriran Ramin
Publication year - 2021
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.30041
Subject(s) - covid-19 , angiotensin converting enzyme 2 , mechanism (biology) , virology , coronavirus , virus , pathogenesis , immunology , disease , endocytosis , viral entry , medicine , biology , outbreak , viral replication , infectious disease (medical specialty) , receptor , genetics , philosophy , epistemology
COVID‐19, a new disease caused by the 2019‐novel coronavirus (SARS‐CoV‐2), has swept the world and challenged its culture, economy, and health infrastructure. Forced emergence to find an effective vaccine to immunize people has led scientists to design and examine vaccine candidates all over the world. Until a vaccine is developed, however, effective treatment is needed to combat this virus, which is resistant to all conventional antiviral drugs. Accordingly, more about the structure, entry mechanism, and pathogenesis of COVID‐19 is required. Angiotensin‐converting enzyme 2 (ACE2) is the gateway to SARS‐CoV and SARS‐CoV‐2, so our knowledge of SARS‐CoV‐2 can help us to complete its mechanism of interaction with ACE2 and virus endocytosis, which can be interrupted by neutralizing small molecules or proteins. ACE2 also plays a crucial role in lung injury.